The significance of QT interval in drug development

Authors


  • Presented at the 3rd Meeting on Clinical Measurement and New Drug Development, Royal Society of Edinburgh, 13–14 June 2001.

    The views expressed in this paper are those of the author and do not necessarily represent the views or the opinions of Medicines Control Agency, other regulatory authorities or any of their advisory committees.

Dr R. R. Shah, Medicines Control Agency, Market Towers, 1 Nine Elms Lane, Vauxhall, London, SW8 5NQ, UK.

Ancillary